Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001324975 | SCV001515947 | pathogenic | not provided | 2023-09-21 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt USH2A protein function. ClinVar contains an entry for this variant (Variation ID: 1024751). This missense change has been observed in individual(s) with clinical features of Usher syndrome (PMID: 26927203, 32675063; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 4331 of the USH2A protein (p.Tyr4331Cys). |
Fulgent Genetics, |
RCV005014424 | SCV005645498 | likely pathogenic | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2024-01-22 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001830366 | SCV002088282 | uncertain significance | Usher syndrome type 2A | 2020-08-12 | no assertion criteria provided | clinical testing |